Characterization of indolinones which preferentially inhibit VEGF-C- and VEGF-D-induced activation of VEGFR-3 rather than VEGFR-2
about
VEGF receptor 2/-3 heterodimers detected in situ by proximity ligation on angiogenic sproutsAutocrine loop between vascular endothelial growth factor (VEGF)-C and VEGF receptor-3 positively regulates tumor-associated lymphangiogenesis in oral squamoid cancer cellsThe lymphangiogenic vascular endothelial growth factors VEGF-C and -D are ligands for the integrin alpha9beta1Notch-dependent VEGFR3 upregulation allows angiogenesis without VEGF-VEGFR2 signallingA transgenic Xenopus laevis reporter model to study lymphangiogenesis.Inflammation induces lymphangiogenesis through up-regulation of VEGFR-3 mediated by NF-kappaB and Prox1.Alternatively spliced vascular endothelial growth factor receptor-2 is an essential endogenous inhibitor of lymphatic vessel growth.In vitro assays using primary embryonic mouse lymphatic endothelial cells uncover key roles for FGFR1 signalling in lymphangiogenesisPeriostin directly and indirectly promotes tumor lymphangiogenesis of head and neck cancer.Tripolin A, a novel small-molecule inhibitor of aurora A kinase, reveals new regulation of HURP's distribution on microtubules.Natural product derived receptor tyrosine kinase inhibitors: identification of IGF1R, Tie-2, and VEGFR-3 inhibitors.The indolinone MAZ51 induces cell rounding and G2/M cell cycle arrest in glioma cells without the inhibition of VEGFR-3 phosphorylation: involvement of the RhoA and Akt/GSK3β signaling pathwaysTumor cell transendothelial passage in the absorbing lymphatic vessel of transgenic adenocarcinoma mouse prostateLymphangiogenesis and hemangiogenesis: potential targets for therapyTaurocholate feeding to bile duct ligated rats prevents caffeic acid-induced bile duct damage by changes in cholangiocyte VEGF expression.Vascular endothelial growth factors C and D induces proliferation of lymphangioleiomyomatosis cells through autocrine crosstalk with endothelium.Macrophage-Induced Lymphangiogenesis and Metastasis following Paclitaxel Chemotherapy Is Regulated by VEGFR3Inhibition of lymphatic metastasis in neuroblastoma by a novel neutralizing antibody to vascular endothelial growth factor-D.Vascular endothelial growth factor-C, a potential paracrine regulator of glomerular permeability, increases glomerular endothelial cell monolayer integrity and intracellular calcium.VEGF-C promotes survival in podocytes.Activation of vascular endothelial growth factor receptor-3 and its downstream signaling promote cell survival under oxidative stress.VEGF-C alters barrier function of cultured lymphatic endothelial cells through a VEGFR-3-dependent mechanism.Inhibition of angiogenesis-relevant receptor tyrosine kinases by sulindac analogues.Vascular endothelial growth factor-C stimulates the lymphatic pump by a VEGF receptor-3-dependent mechanism.Inhibition of VEGFR-3 activation in tumor-draining lymph nodes suppresses the outgrowth of lymph node metastases in the MT-450 syngeneic rat breast cancer model.Neoadjuvant Locoregional Therapy and Recurrent Hepatocellular Carcinoma after Liver Transplantation.Overexpression of VEGF-C attenuates chronic high salt intake-induced left ventricular maladaptive remodeling in spontaneously hypertensive rats.
P2860
Q24302234-2663CD71-C2D5-48D6-8928-21592042C284Q24318473-DC81E454-6851-4A14-A74C-0F4FD7CD8F74Q24538981-A4303EB5-3E5D-4A2F-A115-713E5F02C560Q28587298-738477F2-C9E1-497E-8662-4234D6361BBFQ30544814-423E641F-D7EF-4BB2-8D90-8B43E44756C3Q33597563-1FDEB031-5851-410B-A62F-4A134FF24008Q33899627-36627B78-F918-4542-B5AF-7FDD5AADF1FEQ34336424-61FAADB7-B5BD-4434-8AC2-CBAF5E555B7CQ34406774-88C88465-925B-4C1F-9C67-660F4BD5161EQ34629643-6B4CCC7C-3A2A-4104-A45E-95DD2E5505BAQ35030176-6149860E-6020-4FE0-A890-914958F1EEC6Q35287066-E3D0ABCA-538E-4EEA-B704-F2C645733C67Q35570343-812973EA-A8B0-4323-BB7A-34C53D9F3558Q35575870-33857344-FFB3-4E43-AF5B-8BA51D173C9AQ37157705-C9E5014F-81F8-494F-87BC-1BE58A2C2AB3Q37362046-DC148612-690F-4D57-896D-3090AD8815CAQ37397162-259B9703-E828-48B2-955D-13A31A85D313Q39287689-ABDEDC64-7453-4D76-B120-1FE179EB812EQ39943126-34F6A498-9EAE-4CF2-A496-B7DDB54D7527Q40307403-BE8CE8FA-03C0-444D-8A80-DB495382CD3FQ40563957-A0DB21EF-9E39-44BB-A6F0-685C7CF8D7DAQ41139771-2CC148C6-50DF-4731-B9B6-973AC731C048Q45254680-887F189C-45F6-4032-8D25-5B93A94272D5Q46119200-18F0BC65-79FB-4710-8B80-CD2675707DA9Q46670060-83C2272D-3ED7-403A-8ACE-ACF1E04CA473Q51063111-D7BABE10-D0BE-4779-BD03-2FB0AE305BF8Q54441414-61D5D7DB-35FC-4CF6-938F-AF668F459497
P2860
Characterization of indolinones which preferentially inhibit VEGF-C- and VEGF-D-induced activation of VEGFR-3 rather than VEGFR-2
description
2001 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 2001
@ast
im November 2001 veröffentlichter wissenschaftlicher Artikel
@de
scientific journal article
@en
vedecký článok (publikovaný 2001/11/01)
@sk
vědecký článek publikovaný v roce 2001
@cs
wetenschappelijk artikel (gepubliceerd op 2001/11/01)
@nl
наукова стаття, опублікована в листопаді 2001
@uk
مقالة علمية (نشرت في نوفمبر 2001)
@ar
name
Characterization of indolinone ...... of VEGFR-3 rather than VEGFR-2
@ast
Characterization of indolinone ...... of VEGFR-3 rather than VEGFR-2
@en
Characterization of indolinone ...... of VEGFR-3 rather than VEGFR-2
@nl
type
label
Characterization of indolinone ...... of VEGFR-3 rather than VEGFR-2
@ast
Characterization of indolinone ...... of VEGFR-3 rather than VEGFR-2
@en
Characterization of indolinone ...... of VEGFR-3 rather than VEGFR-2
@nl
prefLabel
Characterization of indolinone ...... of VEGFR-3 rather than VEGFR-2
@ast
Characterization of indolinone ...... of VEGFR-3 rather than VEGFR-2
@en
Characterization of indolinone ...... of VEGFR-3 rather than VEGFR-2
@nl
P2093
P2860
P50
P3181
P1433
P1476
Characterization of indolinone ...... of VEGFR-3 rather than VEGFR-2
@en
P2093
J P Sleeman
J Waltenberger
R Mazitschek
P2860
P304
P3181
P356
10.1046/J.1432-1033.2001.02476.X
P407
P577
2001-11-01T00:00:00Z